• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Efficacy and prognosis of adjuvant treatment of endometrial cancer with medroxyprogesterone acetate COX regression analysis
CONCLUSION: Age, pathological type, molecular typing, and myometrial infiltration were all relevant factors affecting the prognosis of early-stage high-risk endometrial cancer. The potential long-term prognostic benefit of adjuvant postoperative radiotherapy in patients with early-stage high-risk endometrial cancer is worthy of clinical consideration.PMID:37637703 | PMC:PMC10450383 | DOI:10.12998/wjcc.v11.i23.5447
Source: Cancer Control - August 28, 2023 Category: Cancer & Oncology Authors: Ding-Ran Wang Source Type: research

Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery
CONCLUSIONS: The association between ET and having no macroscopic residual disease is plausible given a strong underlying biologic hypothesis between this exposure and diagnosis with HGSC. If this or the parity finding is replicated, these factors could be included in risk stratification models to determine whether HGSC patients should receive PCS or neoadjuvant chemotherapy.PMID:36401943 | DOI:10.1016/j.ygyno.2022.10.018
Source: Ann Oncol - November 19, 2022 Category: Cancer & Oncology Authors: Minh Tung Phung Penelope M Webb Anna DeFazio Sian Fereday Alice W Lee David D L Bowtell Peter A Fasching Ellen L Goode Marc T Goodman Beth Y Karlan Jenny Lester Keitaro Matsuo Francesmary Modugno James D Brenton Toon Van Gorp Paul D P Pharoah Joellen M Sc Source Type: research

A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study
CONCLUSIONS: EL and MT demonstrated clinically meaningful efficacy in recurrent EC patients. The higher PFS observed in chemo-naïve patients is worthy of confirmation in future studies.PMID:35063278 | DOI:10.1016/j.ygyno.2021.12.031
Source: Gynecologic Oncology - January 22, 2022 Category: Cancer & Oncology Authors: Brian M Slomovitz Virginia L Filiaci Joan L Walker Michael C Taub Karen A Finkelstein John W Moroney Aimee C Fleury Carolyn Y Muller Laura L Holman Larry J Copeland David S Miller Robert L Coleman Source Type: research

Hormone replacement therapy after surgery for epithelial ovarian cancer.
CONCLUSIONS: Hormone replacement therapy may slightly improve overall survival in women who have undergone surgical treatment for EOC, but the certainty of the evidence is low. HRT may make little or no difference to quality of life, incidence of breast cancer, TIA, CVA and MI as the certainty of the evidence has been assessed as very low. There may be little or no effect of HRT use on progression-free survival. The evidence in this review is limited by imprecision and incompleteness of reported relevant outcomes and therefore the results should be interpreted with caution. Future well-designed RCTs are required as this is...
Source: Cochrane Database of Systematic Reviews - January 27, 2020 Category: General Medicine Authors: Saeaib N, Peeyananjarassri K, Liabsuetrakul T, Buhachat R, Myriokefalitaki E Tags: Cochrane Database Syst Rev Source Type: research